Aspirin; Methocarbamol

Sold as Robaxisal. Every FDA application for this active ingredient: 1 branded and 4 generic.

As of Nov 15, 2026, FDA lists 5 applications for Aspirin; Methocarbamol (sold as Robaxisal), first approved Apr 15, 1960, with 0 new uses approved and 0 published complete response letters.

First approved: Apr 15, 1960
Applications: 5
New uses approved: 0
Complete response letters: 0

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
Reduce Opiate Exposure With ACL SurgeryAnterior Cruciate Ligament Injuries · Campbell Clinic	Phase 3	Enrolling by invitation	Aug 19, 2024

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Apr 15, 1960	RobaxisalNDA 12281 · New combination	Robins Ah	30	Discontinued
Dec 22, 1982	Methocarbamol And AspirinANDA 87211	Ivax Sub Teva Pharms	23	Discontinued
Feb 12, 1986	Methocarbamol And AspirinANDA 89193	Mcneil	0	Discontinued
Nov 4, 1988	Methocarbamol And AspirinANDA 89657	Par Pharm	5	Discontinued
Jan 31, 1995	Methocarbamol And AspirinANDA 81145	Stevens J	2	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA